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Abstract
Introduction
It is now estimated in the United States alone, there are     
nearly 3.9 million people suffering from chronic HCV,       
with nearly 22,000 new infections yearly. There are   
350,000 HCV related deaths yearly worldwide, with 
approximately15,000 in the United States alone. In 2007,   
the deaths associated with HCV exceeded the mortality   
rates linked to AIDS. As the disease progresses there is
an increased risk of cirrhosis (Fig. 1),  ascites, portal    
hypertension, encephalopathy, and liver cancer  
(Franciscus, 2015). 
Research Question
Literature Review  
• An et al. (2014) reported a SVR of 95% at 12 weeks with
sofosbuvir and ledipasvir. The SVR was 94% with sofosbuvir and
ledispavir at 8 weeks (Table 1).  
• Akoth et al. (2015) stated 76% of patients on a regimen of sofosbuvir,
ledipasvir, and NS3/4A for 6 weeks. Overall 76% of patients retained
a SVR while 22% of patients experienced a viral relapse. 
• Abbott et al. (2015) reported a 4 week treatment using a small 
open-label nonrandomized, clinical trial that examined 25 African 
American genotype 1 patients using sofosbuvir. The study showed 
48% retained a SVR. 
• Harris, Schwab, and Ward (2015) performed a small retrospective
observational cohort study to measure whether the previous response 
guided therapy protocol was applied properly using boceprevir and 
telaprevir. Of 134 patients 15% met the qualifications 
for ending therapy. 
Applicability to Clinical         
Practice
• A standard 12 weeks of therapy could potentially be 
lowered to 6 weeks in select individuals thus lowering 
the treatment costs and side effects. 
• It was noted there is a dire need for clinical pharmacists 
to implement a better strategy to effectively train 
physicians how to incorporate a response guided therapy 
method based on proper guidelines. Proper training is 
essential to avoid longer durations of treatment due to 
lack of knowledge and training given to providers. Discussion
An et al. (2014) demonstrated a high percentage of patients were 
able to achieve a SVR with 8 weeks of treatment using sofosbuvir. 
The authors did not include race or ethnicity as an inclusion criteria.  
Race is definitely an area that needs to be explored more. The study 
was also done on genotype 1 patients. Other genotypes need to be 
evaluated.
Akoth et al. (2015) data suggests that 6 weeks of treatment is 
effective in achieving a SVR in certain individuals. Factors such as 
low viral load and early fibrosis could indicate whether the patient 
should endure a shorter treatment protocol, such as 4 weeks, versus 
the standard 12 weeks. However, more research should be conducted 
with larger sample studies, and should include individuals with a 
decompensated liver (Figure 1).  
Abbott et al. (2015) acknowledged a correlation with achieving a 
SVR in just 4 weeks of treatment in individuals with an HCV RNA 
baseline level of less than 6 million IU/ml. The data suggests 
response guided therapy may be feasible in individuals with a low 
viral load, and are without cirrhosis. However they state that more 
research is needed with a larger population size and race.
Harris, Schwab, and Ward (2015) suggest providers do not follow the 
response guided therapy protocol properly, due to the provider’s lack 
of knowledge and proper training with the treatment, and the fear of 
discontinuing the drug too early. The authors state that managed care 
pharmacists need to implement strategies that will aim for better 
physician training and compliance with the response guided therapy 
guidelines, if it were ever implemented for sofosbuvir. 
The data suggests response guided therapy may be feasible in 
individuals with a low viral load, and are without cirrhosis. Research 
limitations include small population size, race, and viral load. 
Provider knowledge is essential in response guided therapy plans, as 
many providers did not follow the protocol properly and 
discontinued treatment later than needed. 
Pharmacologic advances have been made with the 
development of new drug therapies that essentially cure the 
hepatitis C virus, such as sofosbuvir. The purpose of this 
study is to determine whether sofosbuvir should encompass a 
response guided therapy treatment plan versus a standard 
treatment protocol, in efforts to limit the risk of adverse 
effects and to minimize the cost of treatment. The systematic 
review of literature retrieved from Pub Med and Cochrane, 
explored studies that compared a standard treatment protocol 
of 12 weeks, in male and female adults ages 18-90 years, to 
response guided therapy treatment plans based on each 
individual’s sustained virologic response. Reducing the 
duration of treatment will decrease the risk of adverse side 
effects, and lower the cost of therapy. This information will 
help practitioners guide appropriate length of HCV treatment 
based on each individual patient, to ensure a sustained viral 
load. 
The purpose of this study was to determine whether the 
pharmacologic regimen, sofosbuvir, for the management of 
chronic HCV should encompass a response guided therapy 
treatment plan versus a standard treatment protocol, in efforts to 
limit the risk of adverse side effects and to greatly minimize the 
cost of treatment.
Statement of the Problem
Pharmacologic advances have been made in recent years 
with the development of new drug therapies, such as, 
sofosbuvir, which essential “cures” HCV by eradicating 
the RNA viral load from the system. Nonetheless, these 
pharmacologic remedies are costly, averaging roughly a 
$1000 per pill daily, for a minimum of 12-24 weeks. In 
addition, there are many side effects that affect drug 
adherence such as hemolytic anemia, depression, nausea, 
vomiting, or diarrhea. 
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HCV RNA <25 IU/ml    
During treatment period- no./total 
no. % 
   
 







At wk 4 215/215 (100) 211/213 (99) 216/216 (100) 
After end of treatment-no. (%)    
At wk 4 207 (96) 205 (95) 208 (96) 
At wk 12 202 (94) 201 (93) 206 (95) 
Virologic failure during treatment 0 0 0 
Relapse in pts with HCV RNA < 25 







Lost to follow up 1 5 7 
Withdrew consent 1 1 0 
  N= number of patients                     LDV= ledipasvir                 SOF= sofosbuvir                     RBV= ribavirin 
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Figure 1. Liver Cirrhosis
